Proactive Investors
10 Nov 2025, 14:15 UTC · 45w ago
Verdict
Headline takes no side. We score ATAI +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
AtaiBeckley's Phase 2b OLE data support advancing the 8 mg dose of BPL-003 into Phase 3 development for treatment-resistant depression.
More positive than 99% of claims this week
The 8 mg dose group achieved a 67% remission rate and 81% responder rate at Day 57 in the open-label extension study.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 97% of claims this week
The company has scheduled an End-of-Phase 2 meeting with the FDA and expects Phase 3 guidance in Q1 2026.
More positive than 92% of claims this week
Two doses of BPL-003 given eight weeks apart provided antidepressant effects lasting up to four months, supporting an intermittent-dose treatment paradigm.
More positive than 85% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company reported positive topline results from a Phase 2b clinical trial for treatment-resistant depression and is planning Phase 3 development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
6h ago
+68.6%
Price agrees with the score
$7.35 vs $4.36 close before publication (Nov 7) · not market-adjusted
ATAI chart →
